Univest
Univest
  • Markets

Alkyl Amines Analyst Review 2027: Profit Up 52% in Q2, but Coverage Is Thin and the Stock Is 24% Off Its High

  • November 18, 2026
  • Posted by: Kunal Singla
  • Category: Market
No Comments
Alkyl Amines Analyst Review 2027: Profit Up 52% in Q2, but Coverage Is Thin and the Stock Is 24% Off Its High

Alkyl Amines Chemicals Stock Snapshot (17 Nov 2026 close)

  • Current Market Price (CMP): ₹1,610.10
  • 52-Week High / Low: ₹2,115.00 / ₹1,212.00
  • Market Capitalisation: ₹8,234 crore
  • P/E Ratio vs Industry P/E: 33.3 vs 36.4
  • Latest Quarter (Q2 FY27) Revenue: ₹490.95 crore
  • Latest Quarter (Q2 FY27) Net Profit: ₹65.17 crore

Quick Answer: The Alkyl Amines analyst review 2027 starts with a clear earnings recovery but limited research coverage. Q2 FY27 revenue rose about 26% to ₹490.95 crore and profit rose about 52% to ₹65.17 crore, after a 91% profit jump in Q1. No recent named brokerage target could be verified, so there is no reliable published Alkyl Amines share price target 2027. At ₹1,610.10, the stock trades about 24% below its 52-week high and at a P/E near 33, slightly below its industry.

The Alkyl Amines analyst review 2027 covers India’s leading maker of aliphatic amines, chemicals used by pharma, agrochemical and water treatment companies. Readers looking for an Alkyl Amines share price target 2027 should know that brokerage coverage is thin, so this review leans on reported results and the industry cycle.

Alkyl Amines Chemicals closed at ₹1,610.10 on 17 November 2026, about 24% below its 52-week high of ₹2,115 and about 33% above its low of ₹1,212. This Alkyl Amines analyst review 2027 covers what the numbers show, how the business works and the Alkyl Amines stock outlook 2027.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Analysts Say in the Alkyl Amines Analyst Review 2027
  • Q2 FY27 Results in the Alkyl Amines Analyst Review 2027
  • How Alkyl Amines Makes Money
  • Growth Triggers in the Alkyl Amines Analyst Review 2027
  • Key Risks in the Alkyl Amines Analyst Review 2027
  • Alkyl Amines Analyst Review 2027: Stock at a Glance
  • Shareholding Trend
  • What to Watch After the Alkyl Amines Analyst Review 2027
  • Final Word on the Alkyl Amines Analyst Review 2027
  • Frequently Asked Questions
    • What does the Alkyl Amines analyst review 2027 show?
    • Is there an Alkyl Amines share price target 2027 from brokerages?
    • How did Alkyl Amines perform in H1 FY27?
    • What does Alkyl Amines make?
    • Is Alkyl Amines expensive, based on the Alkyl Amines analyst review 2027?
    • What risks does the Alkyl Amines analyst review 2027 highlight?
    • What should investors track after the Alkyl Amines analyst review 2027?

What Analysts Say in the Alkyl Amines Analyst Review 2027

Brokerage Rating Target Price Date
No verified recent coverage Not available Not available As of November 2026

No dated brokerage report with a rating and target from FY27 could be traced for Alkyl Amines. Institutional ownership is low, with foreign and domestic institutions together holding under 7%, and the company does not draw the same research attention as larger chemical makers.

That shapes how to read the Alkyl Amines analyst review 2027. Without consensus estimates, each quarterly result moves the stock more than usual. Any target that circulates without a named, registered source should be treated with caution.

What can be tracked is the earnings trend. Profit has risen sharply in both quarters of FY27 after a weak FY26, when the company described results as broadly flat and proposed a ₹10 per share dividend.

Q2 FY27 Results in the Alkyl Amines Analyst Review 2027

Metric Q2 FY27 Q1 FY27
Revenue from Operations ₹490.95 crore (+26.1% YoY) ₹528 crore (+30.2% YoY)
Net Profit ₹65.17 crore (+51.8% YoY) About ₹94.6 crore (+91% YoY)
Profit Before Tax ₹90.09 crore Not used here
H1 FY27 Revenue ₹1,039.03 crore
H1 FY27 Net Profit ₹159.80 crore

Revenue from operations rose about 26.1% to ₹490.95 crore in Q2 FY27, and profit rose about 51.8% to ₹65.17 crore. Profit before tax was ₹90.09 crore. Profit grew about twice as fast as revenue, which points to better pricing and plant utilisation.

Compared with the June quarter, revenue and profit were lower. Q1 FY27 revenue was about ₹528 crore and profit about ₹94.6 crore, with EBITDA margin near 25.3%. For the Alkyl Amines analyst review 2027, the trend is still strong year on year, but the sequential dip is worth watching. H1 FY27 profit of ₹159.80 crore is already a large share of what a normal full year has looked like.

How Alkyl Amines Makes Money

Alkyl Amines, founded in 1979 by Yogesh Kothari, makes aliphatic amines and related chemicals at plants in Maharashtra and Gujarat.

  • Methylamines and ethylamines: base chemicals used across pharma and agrochemical synthesis.
  • Amine derivatives: higher-value products made from basic amines.
  • Specialty chemicals: products for water treatment, rubber chemicals, solvents and other uses.
  • Exports: a share of sales goes to global customers in pharma and agrochemicals.

Profit depends on the spread between selling prices and raw material costs such as methanol, ammonia and ethanol. When supply from China rises, prices fall and margins shrink. When demand recovers, the operating gains can be large, as FY27 so far shows. This sensitivity to the cycle is the core of the Alkyl Amines analyst review 2027.

Growth Triggers in the Alkyl Amines Analyst Review 2027

  • Cycle recovery: two quarters of strong profit growth suggest the amine downcycle has eased.
  • Sector peers: Balaji Amines also reported revenue up about 36% in Q2 FY27, which supports a broad recovery view.
  • Pharma and agro demand: both end markets are recovering after inventory cuts.
  • Balance sheet: debt to equity of about 0.01 means almost no borrowings.
  • Return on equity: about 15%, which should rise if FY27 profit holds near the H1 run rate, a key test in the Alkyl Amines analyst review 2027.

Key Risks in the Alkyl Amines Analyst Review 2027

  • Chinese supply: fresh capacity or dumping can push amine prices down quickly.
  • Raw material swings: methanol and ammonia costs affect margins each quarter.
  • Sequential slowdown: Q2 FY27 profit was lower than Q1 FY27.
  • No research coverage: no named targets exist to anchor expectations.
  • Low institutional base: institutions hold under 7%, so liquidity depends on retail holders.
  • Valuation after recovery: a P/E near 33 already prices in part of the upturn.

Compare Alkyl Amines With Specialty Chemical Stocks on the Univest Screener

Alkyl Amines Analyst Review 2027: Stock at a Glance

Metric Value
Share Price (17 Nov 2026 close) ₹1,610.10
52-Week High / Low ₹2,115.00 / ₹1,212.00
Market Capitalisation ₹8,234 crore
P/E (TTM) vs Industry 33.3 vs 36.4
Price to Book 5.02
Book Value per Share ₹320.95
Return on Equity 15.07%
Debt to Equity 0.01
Dividend Yield 0.62%
EPS (TTM) ₹48.38

The stock trades at a slight discount to its industry P/E, with a price to book value of about 5. Trailing earnings include the weak second half of FY26, so the multiple would fall if FY27 profit holds near the H1 pace. In the Alkyl Amines analyst review 2027, valuation looks reasonable only if the recovery lasts.

Shareholding Trend

Holder Sep 2025 Sep 2026 Change
Promoters 72.03% 72.04% +0.01 pts
Foreign Investors (FII) 3.43% 3.46% +0.03 pts
Domestic Institutions (DII) 2.88% 3.26% +0.38 pts
Public 21.66% 21.24% -0.42 pts

The promoter group holds a steady 72.04%, with founder Yogesh Kothari at 57.64%. Institutional holdings barely moved over the year. A rise in institutional buying would be an early signal that the recovery story in the Alkyl Amines analyst review 2027 is gaining wider acceptance.

Univest iOS App

Univest Android App

What to Watch After the Alkyl Amines Analyst Review 2027

  • Q3 FY27 margins: whether profit growth stays strong after the dip from Q1 to Q2.
  • Amine prices: trends in Chinese export prices for key amines.
  • Raw materials: methanol and ammonia cost movements.
  • Full-year profit: whether FY27 beats FY26 by a wide margin, given H1 profit of ₹159.80 crore.
  • Research coverage: a first named note would give an Alkyl Amines share price target 2027 reference point.

Final Word on the Alkyl Amines Analyst Review 2027

The Alkyl Amines analyst review 2027 shows a debt-free chemical maker in the middle of a cyclical recovery, with Q2 FY27 profit up about 52% and H1 profit at ₹159.80 crore. The stock still trades about 24% below its high, and there is no verified brokerage target to guide expectations.

The Alkyl Amines stock outlook 2027 depends on amine prices, raw material costs and whether margins hold through the second half. Univest does not give a buy or sell call.

Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.

Frequently Asked Questions

What does the Alkyl Amines analyst review 2027 show?

It shows a strong earnings recovery with limited research coverage. Q2 FY27 revenue rose about 26.1% to ₹490.95 crore and profit rose about 51.8% to ₹65.17 crore. No recent named brokerage target could be verified.

Is there an Alkyl Amines share price target 2027 from brokerages?

No verified recent brokerage target exists as of November 2026. Institutions hold under 7% of the company, which limits research interest. The stock closed at ₹1,610.10 on 17 November 2026.

How did Alkyl Amines perform in H1 FY27?

H1 FY27 revenue was ₹1,039.03 crore and profit was ₹159.80 crore. Q1 profit rose about 91% and Q2 profit rose about 52% from a year earlier. Q2 profit was lower than Q1 on a sequential basis.

What does Alkyl Amines make?

It makes aliphatic amines such as methylamines and ethylamines, plus derivatives and specialty chemicals. These go into pharma, agrochemicals, water treatment and rubber chemicals. The company was founded in 1979 by Yogesh Kothari.

Is Alkyl Amines expensive, based on the Alkyl Amines analyst review 2027?

The P/E of about 33.3 is slightly below the industry figure of about 36.4. Price to book is about 5 and return on equity is about 15%. Trailing earnings include the weak second half of FY26.

What risks does the Alkyl Amines analyst review 2027 highlight?

The main risks are Chinese supply pushing amine prices down and swings in methanol and ammonia costs. Q2 FY27 profit was lower than Q1. There is also no named research coverage to anchor expectations.

What should investors track after the Alkyl Amines analyst review 2027?

Track Q3 FY27 margins and whether profit growth continues. Watch Chinese amine export prices and raw material costs. Full-year FY27 profit against the H1 figure of ₹159.80 crore is the main test.



2027 Alkyl Amines Chemicals Analyst Review specialty chemicals
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply